Cejka A Timothy Form 4 December 13, 2005

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL** OMB

3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

10% Owner

\_\_ Other (specify

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person \* Cejka A Timothy

2. Issuer Name and Ticker or Trading Symbol

EXXON MOBIL CORP [XOM]

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(First)

(Street)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 12/12/2005

Filed(Month/Day/Year)

(Check all applicable)

C/O EXXON MOBIL CORP, 5959 LAS COLINAS BLVD

4. If Amendment, Date Original

\_X\_\_ Officer (give title \_ below) Vice President

Director

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting Person

IRVING, TX 75039-2298

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secu	rities Acquii	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	omr Dispos (Instr. 3, 4	ed of (4 and 5 (A) or	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/12/2005		Code V M	Amount 36,000	(D)	Price \$ 30.7031	216,475	D	
Common Stock	12/12/2005		S	30,400	D	\$ 58.5	186,075	D	
Common Stock	12/12/2005		S	2,344	D	\$ 58.56	183,731 (1)	D	
Common Stock							5,854.3704	I	By Savings Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secur Secur Acqu or Di (D)	rities ired (A) sposed of : 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 30.7031	12/12/2005		M		36,000	11/26/1998	11/26/2007	Common Stock	36,000

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Cejka A Timothy C/O EXXON MOBIL CORP 5959 LAS COLINAS BLVD

IRVING, TX 75039-2298

Vice President

# **Signatures**

A. T. Cejka 12/13/2005

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 14,284 shares in joint ownership with reporting person's spouse.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. 10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,639

Reporting Owners 2

Edgar Filing: Cejka A Timothy - Form 4 Other 1,650 381 (35 ) 1,996

2,554

706

(243

)

3,017

7,770

1,711

(61

)

9,420

11,139

2,367 (481 ) 13,025 Certificates of deposit 3,950 2 (2 )

3,950

5,101

3

\_

5,104

\$

243,666

\$

1,804

81
45,389
200,509
2,580
497
02,592
a)Includes \$8.5 million and \$3.7 million of money market funds at December 31, 2013 and 2012, respectively.

The fair value by maturity periods at December 31, 2013 of available-for-sale investments of the Company's insurance subsidiary follows. Equities generally do not have maturity dates.

	Contractual
(In thousands)	maturities
Within one	
year	\$ 198,441
One year to	
five years	37,528
After five	
years	_
Equities	9,420
	\$ 245,389

Since the Company's insurance subsidiary investments are restricted for a limited purpose, they are classified in the accompanying consolidated balance sheet based upon the expected current and long-term cash requirements of the limited purpose insurance subsidiary.

Net investment income earned by the Company's insurance subsidiary investments follows (in thousands):

	Year ended
	December 31,
	2013 2012 2011
Interest income	\$1,011 \$1,290 \$1,399
Net amortization of premium and accretion of discount	(330 ) (406 ) (322 )
Gains on sale of investments	3,404 123 265
Losses on sale of investments	(24 ) (28 ) (73 )
Other-than-temporary impairments	(143) – (232)
Investment expenses	(118) (115) (119)
	\$3,800 \$864 \$918

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 10 – INSURANCE SUBSIDIARY INVESTMENTS (Continued)

The available-for-sale investments of the Company's insurance subsidiary which have unrealized losses at December 31, 2013 and 2012 are shown below. The investments are categorized by the length of time that individual securities have been in a continuous unrealized loss position at December 31, 2013 and 2012.

			One year or		
December 31, 20	13 Less than	one year	greater	Total	
	Fair	Unrealized	d Fair Unrealize	ed Fair	Unrealized
(In thousands)	value	losses	value losses	value	losses
Debt securities:					
Corporate bonds	\$4,699	\$ 8	\$53 \$ -	\$4,752	\$ 8
Debt securities issued by U.S.					
government agencies	4,916	8		4,916	8
U.S. Treasury notes	1,618	2		1,618	2
	11,233	18	53 –	11,286	18
Equities by industry:					
Consumer	717	21		717	21
Healthcare	161	3		161	3
Financial services	194	2		194	2
Other	612	35		612	35
	1,684	61		1,684	61
Certificates of deposit	747	2		747	2
	\$13,664	\$ 81	\$53 \$ -	\$13,717	\$ 81

December 31, 2012	Less than one year		One year or greater		Total				
	Fair	Ur	realized	Fair	U	nrealized	Fair	U	nrealized
(In thousands)	value	los	sses	value	lo	sses	value	lo	sses
Debt securities:									
Corporate bonds	\$4,115	\$	7	\$257	\$	9	\$4,372	\$	16
Equities by industry:									
Consumer	-		-	234		15	234		15
Industrials	-		-	367		53	367		53
Technology	_		_	482		70	482		70
Healthcare	78		9	188		5	266		14
Financial services	48		1	339		85	387		86
Other	343		45	416		198	759		243
	469		55	2,026		426	2,495		481
	\$4,584	\$	62	\$2,283	\$	435	\$6,867	\$	497

The unrealized losses on equities totaling \$0.1 million at December 31, 2013 and \$0.5 million at December 31, 2012 were due generally to market fluctuations. Accordingly, the Company believes these unrealized losses are temporary in nature.

The Company's investment policy governing insurance subsidiary investments precludes the investment portfolio managers from selling any security at a loss without prior authorization from the Company. The investment managers also limit the exposure to any one issue, issuer or type of investment. The Company intends, and has the ability, to hold insurance subsidiary investments for a long duration without the necessity of selling securities to fund the underwriting needs of its insurance subsidiary. This ability to hold securities allows sufficient time for recovery of temporary declines in the market value of equity securities and the par value of debt securities as of their stated maturity date.

The Company considered the severity and duration of its unrealized losses at December 31, 2013 and recognized a \$0.1 million pretax other-than-temporary impairment during 2013 for various investments held in its insurance subsidiary investment portfolio. The Company recognized \$0.2 million pretax other-than-temporary impairments in 2011 for various investments held in its insurance subsidiary investment portfolio. These investments were determined to be impaired after considering the duration of the declines in value and the likelihood of near term price recovery of each investment. Because the Company considered the remaining unrealized losses at December 31, 2013 and 2012 to be temporary, the Company did not record any additional impairment losses related to these investments.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 10 – INSURANCE SUBSIDIARY INVESTMENTS (Continued)

As a result of deterioration in professional liability and workers compensation underwriting results of the Company's limited purpose insurance subsidiary in 2012 and 2011, the Company made capital contributions of \$14.2 million and \$8.6 million in 2013 and 2012, respectively, to its limited purpose insurance subsidiary. Conversely, as a result of improved professional liability underwriting results of the Company's limited purpose insurance subsidiary in 2010, the Company received a distribution of \$3.5 million in 2011 from its limited purpose insurance subsidiary. These transactions were completed in accordance with applicable regulations. Neither the capital contributions nor the distribution had any impact on earnings.

#### NOTE 11 – LEASES

The Company leases real estate and equipment under cancelable and non-cancelable arrangements. The following table sets forth rent expense by business segment (in thousands):

	Year ended December 31,				
	2013	2012	2011		
Hospital division:					
Buildings:					
Ventas	\$107,431	\$101,831	\$94,320		
Other landlords	66,357	70,473	55,301		
Equipment	33,280	33,021	29,314		
	207,068	205,325	178,935		
Nursing center division:					
Buildings:					
Ventas	49,414	47,668	45,819		
Other landlords	40,133	37,823	37,461		
Equipment	9,259	8,211	7,637		
	98,806	93,702	90,917		
Rehabilitation division:					
Skilled nursing rehabilitation services:					
Buildings	1,311	1,289	817		
Equipment	3,415	4,153	5,567		
	4,726	5,442	6,384		
Hospital rehabilitation services:					
Buildings	37	52	120		
Equipment	69	88	108		
	106	140	228		
Care management division:					
Buildings	4,513	2,754	1,199		
Equipment	588	386	167		
	5,101	3,140	1,366		
Corporate:					

Buildings	2,103	2,242	3,356
Equipment	167	187	144
	2,270	2,429	3,500
	\$318 077	\$310 178	\$281 330

Various facility leases include contingent annual rent escalators based upon a change in the Consumer Price Index or other agreed upon terms such as a patient revenue test. These contingent rents are included in rent expense in the year incurred. The Company recorded contingent rent of \$2.5 million, \$1.3 million and \$1.1 million for the years ended December 31, 2013, 2012 and 2011, respectively, including both continuing operations and discontinued operations.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 11 – LEASES (Continued)

Future minimum payments under non-cancelable operating leases are as follows (in thousands):

Minimum payments					
,	Ventas	Other	Total		
2014	\$206,864	\$100,254	\$307,118		
2015	174,415	88,933	263,348		
2016	176,315	81,900	258,215		
2017	178,262	65,315	243,577		
2018	143,957	54,322	198,279		
Thereafter	607,446	263,550	870,996		

Ventas master lease agreements

At December 31, 2013, the Company leased from Ventas and its affiliates 38 TC hospitals and 105 nursing centers under five master lease agreements (as amended, the "Master Lease Agreements"). Included in the 105 nursing centers leased at December 31, 2013 are the 2013 Expiring Facilities, all of which have lease terms expiring on September 30, 2014. For accounting purposes, the 2013 Expiring Facilities qualify as assets held for sale and the Company has reflected the operating results as discontinued operations in the accompanying consolidated statement of operations for all historical periods.

There are several bundles of leased properties under each Master Lease Agreement, with each bundle containing approximately seven to 19 leased nursing centers and/or TC hospitals.

2012 lease renewals and expirations

Under the Master Lease Agreements, the Company had 73 nursing centers and 16 TC hospitals eligible for renewal prior to an April 30, 2013 lease expiration date. In April 2012, the Company renewed the leases for 19 nursing centers and six TC hospitals for an additional five years. In May 2012, the Company entered into a fifth Master Lease Agreement with Ventas to extend the lease term for ten years for ten TC hospitals that were otherwise scheduled to expire on April 30, 2013 ("Master Lease No. 5"). These 19 nursing centers and 16 TC hospitals contain 2,178 licensed nursing center beds and 1,682 licensed hospital beds.

In addition, the Company did not renew 54 nursing centers that comprised the 2012 Expiring Facilities. The 2012 Expiring Facilities contained 6,140 licensed nursing center beds and generated revenues of approximately \$475 million for the year ended December 31, 2012. The annual rent for these facilities approximated \$57 million. The Company transferred the operations of all of the 2012 Expiring Facilities to new operators during 2013 and has accordingly reclassified the results of operations and losses associated with the 2012 Expiring Facilities to discontinued operations, net of income taxes, for all periods presented.

2013 lease renewals and expirations

Under the Master Lease Agreements, the Company had 86 nursing centers and 22 TC hospitals eligible for renewal prior to an April 30, 2015 lease expiration date. On September 30, 2013, the Company entered into an agreement with Ventas to renew the leases for 26 nursing centers and 22 TC hospitals (the "2013 Renewal Facilities") as follows:

- •the leases for 15 nursing centers and three TC hospitals were renewed for an additional five year term effective May 1, 2015, with annual rents increasing by \$4.0 million on October 1, 2014 and otherwise subject to rent escalators found in the original Master Lease Agreements; and
- •the leases for 11 nursing centers and 19 TC hospitals will be moved to an amended and restated Master Lease No. 5 ("Amended Master Lease No. 5") and renewed for a 10 year, seven month term effective October 1, 2014, with annual rents under Amended Master Lease No. 5 increasing by \$11.0 million on October 1, 2014 and otherwise subject to annual increases (up to a 4% cap) based on changes in the Consumer Price Index.

For accounting purposes, the Company began recording the additional rents for the 2013 Renewal Facilities over the new lease term on a straight-line basis beginning on October 1, 2013, the effective date of the agreements.

The 2013 Renewal Facilities contain 3,134 licensed nursing center beds and 1,753 licensed hospital beds and generated revenues of approximately \$811 million for the year ended December 31, 2013. The current aggregate annual rent, before the rent increases noted above, for the 2013 Renewal Facilities approximates \$79 million.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 11 – LEASES (Continued)

2013 lease renewals and expirations (Continued)

On September 30, 2013, the Company also entered into agreements for the 2013 Expiring Facilities. The current lease term for the Renewal Facilities and the 2013 Expiring Facilities was scheduled to expire in April 2015. Under the terms of the agreements, the lease term for the 2013 Expiring Facilities will now expire on September 30, 2014. The September agreement with Ventas also provided for (1) more flexibility to Ventas to accelerate the transfer of the 2013 Expiring Facilities, (2) a \$20 million payment by us to Ventas as part of this transaction that is recorded as an early lease termination charge (rent expense) in discontinued operations in 2013, and (3) the settlement of other matters between the parties.

The 2013 Expiring Facilities contain 7,070 licensed beds and generated revenues of approximately \$514 million for the year ended December 31, 2013. The current aggregate annual rent for the 2013 Expiring Facilities approximates \$60 million.

Except as noted below, the terms of Amended Master Lease No. 5 are substantially similar to the terms of the other Master Lease Agreements.

#### Renewals

Following the exit of the 2013 Expiring Facilities, the Company will lease 45 nursing centers and 38 TC hospitals from Ventas within eight separate renewal bundles. Except as noted below, each bundle may be renewed for at least one five-year renewal term, provided notice of renewal is provided between 12 and 18 months prior to the expiration of the lease term. The following chart sets forth the current lease renewals under the existing Master Lease Agreements:

Hacilit	v ranavial	C
raciiii	y renewal	ю

Renewal group	Master lease	Expiration date Renewal date	Nursing centers	TC s hospitals	Renewal sbundles
Group 1	1, 2, 4	April 30, 2018 October 31, 2016 – April 29, 20	1719	6	3
Group 2	1, 2	April 30, 2020 October 31, 2018 - April 29, 20	1915	3	2
Group 3	5	April 30, 2023 October 31, 2021 – April 29, 202	22–	10	1
Group 4	5	April 30, 2025 October 31, 2023 – April 29, 202	2411	19	2

Conditions to effectiveness of renewals

The Company may not extend the Master Lease Agreements beyond any previously exercised renewal term if, at the time the Company seeks such extension and at the time such extension takes effect: (1) an event of default has occurred and is continuing or (2) a Medicare/Medicaid event of default and/or a licensed bed event of default has occurred and is continuing with respect to one, two or three leased properties, depending on the number of leased properties under a particular Master Lease Agreement. The renewal term of each Master Lease Agreement is subject to termination upon default by the Company and certain other conditions described in the Master Lease Agreements.

Under each Master Lease Agreement, an event of default will be deemed to occur if, among other things, an event of default arises from the Company's failure to pay principal or interest on any indebtedness exceeding \$50 million or the maturity of any indebtedness exceeding \$50 million is accelerated.

Rent appraisal process and the Company's right to revoke such renewals

Under the Master Lease Agreements, if the Company provides Ventas with notice that the Company intends to renew one or more renewal bundles, Ventas may then initiate an appraisal process to establish a new fair market rental (as defined in the Master Lease Agreements) ("FMR") for any or all of these bundles.

Under the appraisal process, an independent appraiser determines the FMR for each renewal bundle and each property within such renewal bundle. Once FMR is determined, the appraiser sends to both parties simultaneously the aggregate FMR for such renewal bundle and the FMR for each property within the bundle. Ventas, in its sole discretion, then determines whether: (1) to accept the appraised FMR for the renewal bundle in the aggregate or (2) make no changes to the current base rent and contingent annual rent escalator for the renewal bundle. If Ventas selects the new FMR for a renewal bundle, then the new FMR would become effective at the start of the renewal term unless the Company elects to revoke its renewal by the applicable deadline set forth in the Master Lease Agreements.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 11 – LEASES (Continued)

Rent appraisal process and the Company's right to revoke such renewals (Continued)

The determination of FMR requires certain levels of subjectivity and judgment related to the many variables that may be considered under the circumstances. As a result, it is important for investors to consider the possibility of a wide range of outcomes with respect to the appraisal process.

#### NOTE 12 - LONG-TERM DEBT

#### Capitalization

A summary of long-term debt at December 31 follows (in thousands):

	2013	2012
Term Loan Facility, net of unamortized original issue discount of \$6.4 million at		
December 31, 2013 and \$7.8 million at December 31, 2012	\$777,197	\$781,694
Notes	550,000	550,000
ABL Facility	256,100	320,700
Capital lease obligations	5	609
Other	4,311	4,645
Total debt, average life of 5 years (weighted average rate 5.4% for 2013 and 5.9% for 2012)	1,587,613	1,657,648
Amounts due within one year	(8,222)	(8,942)
Long-term debt	\$1,579,391	\$1,648,706

The following table summarizes scheduled maturities of long-term debt for the years 2014 through 2018 (in thousands):

Term Loan		ABL	Capital		
Facility	Notes	Facility	leases	Other	Total
2014\$ 7,875	\$ -	\$-	\$ 5	\$342	\$8,222
2015 7,875	_	_	_	3,836	11,711
2016 7,875	_	_	_	123	7,998
2017 7,875	_	_	_	10	7,885
2018 752,062	_	256,100	_	_	1,008,162

The estimated fair value of the Company's long-term debt approximated \$1.6 billion at both December 31, 2013 and December 31, 2012. See Note 17.

Credit facilities and notes

In connection with the RehabCare Merger, the Company entered into the Credit Facilities and issued the Notes. In 2011, the Company used proceeds from the Credit Facilities and the Notes to pay the Merger Consideration, repay all amounts outstanding under the Company's and RehabCare's previous credit facilities and to pay transaction costs. The amounts outstanding under the Company's and RehabCare's former credit facilities that were repaid at the RehabCare Merger closing were \$390.0 million and \$345.4 million, respectively.

The agreements governing the Credit Facilities and the indenture governing the Notes include a number of restrictive covenants that, among other things and subject to certain exceptions and baskets, impose operating and financial restrictions on the Company and certain of its subsidiaries. The Company's ability to pay dividends is limited to certain restricted payment baskets, which may expand based upon accumulated earnings. In addition, the Company is required to comply with a minimum fixed charge coverage ratio and a maximum total leverage ratio under the Credit Facilities. The financing agreements governing the Credit Facilities and the indenture governing the Notes also contain customary affirmative covenants and events of default. The Company was in compliance with the terms of the Credit Facilities and the indenture governing the Notes at December 31, 2013.

All obligations under the Credit Facilities are fully and unconditionally guaranteed, subject to certain customary release provisions, by substantially all of the Company's existing and future direct and indirect domestic 100% owned subsidiaries, as well as certain non-100% owned domestic subsidiaries as the Company may determine from time to time in its sole discretion. The Notes are fully and unconditionally guaranteed, subject to certain customary release provisions, by substantially all of the Company's domestic 100% owned subsidiaries. In addition, the Credit Facilities are collateralized by substantially all of the Company's assets, including certain owned real property.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 12 – LONG-TERM DEBT (Continued)

Credit facilities and notes (Continued)

In August 2013, the Company completed amendments and restatements to the Credit Facilities to increase its borrowing capacity and to modify certain covenants to improve its financial flexibility. The amendments include, among other things, the following changes: (a) refreshing the option to increase the credit capacity in the aggregate between the Credit Facilities by \$250 million; (b) establishing the option to further increase the credit capacity between the Credit Facilities upon satisfaction of a secured leverage ratio; (c) extending the maturity of the ABL Facility by two years to June 2018; (d) eliminating the annual and cumulative limitations on acquisitions; (e) raising to \$150 million the Company's basket for paying cash dividends, buying back stock and making other restricted payments; and (f) easing the restrictions on the Company's ability to make investments and enter into other joint venture arrangements. The interest rate pricing levels were not changed in connection with the amendments.

In May 2013, the Company completed an amendment and restatement of its Term Loan Facility to reduce its annual interest cost by 100 basis points. The applicable interest rate on the Term Loan Facility was reduced by 50 basis points to LIBOR plus 325 basis points (previously LIBOR plus 375 basis points). In addition, the LIBOR floor was reduced to 1.00% from 1.50%.

The Company recorded fees associated with the amendments of \$0.5 million during 2013, which are included in other operating expenses in the accompanying consolidated statement of operations. The Company also recorded charges associated with the amendments and restatements of \$1.5 million during 2013, which are included in interest expense in the accompanying consolidated statement of operations.

The Credit Facilities also included an option to increase the credit capacity in an aggregate amount between the two facilities by \$200 million. In October 2012, the Company exercised this option to increase the credit capacity by completing modifications to increase by \$100 million its Term Loan Facility and expand by \$100 million the borrowing capacity under its ABL Facility. The additional Term Loan Facility borrowings were issued at 97.5% and the net proceeds were used to pay down a portion of the outstanding balance under the ABL Facility. In connection with the \$100 million expansion of the borrowing capacity under its ABL Facility, the Company also modified the accounts receivable borrowing base which will allow the Company to more easily access the full amount of the available credit. The other terms of the Term Loan Facility and the ABL Facility were unchanged.

#### Interest rate swaps

In December 2011, the Company entered into two interest rate swap agreements to hedge its floating interest rate on an aggregate of \$225 million of debt outstanding under its Term Loan Facility. The interest rate swaps have an effective date of January 9, 2012, and expire on January 11, 2016. The Company is required to make payments based upon a fixed interest rate of 1.8925% calculated on the notional amount of \$225 million. In exchange, the Company will receive interest on \$225 million at a variable interest rate that is based upon the three-month LIBOR, subject to a minimum rate of 1.5%. The Company determined the interest rate swaps continue to qualify for cash flow hedge accounting treatment at December 31, 2013. However, the Term Loan Facility amendment completed in May 2013 reduced the LIBOR floor from 1.5% to 1.0%, therefore some partial ineffectiveness will result through the expiration

of the interest rate swap agreement. For the year ended December 31, 2013, there was \$0.4 million of ineffectiveness recognized related to the interest rate swaps recorded in interest expense. The fair value of the interest rate swaps recorded in other accrued liabilities was \$1.4 million and \$2.6 million at December 31, 2013 and December 31, 2012, respectively.

#### **NOTE 13 – CONTINGENCIES**

Management continually evaluates contingencies based upon the best available information. In addition, allowances for losses are provided currently for disputed items that have continuing significance, such as certain third party reimbursements and deductions that continue to be claimed in current cost reports and tax returns.

Management believes that allowances for losses have been provided to the extent necessary and that its assessment of contingencies is reasonable.

Principal contingencies are described below:

Revenues – Certain third party payments are subject to examination by agencies administering the various reimbursement programs. The Company is contesting certain issues raised in audits of prior year cost reports.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 13 – CONTINGENCIES (Continued)

Professional liability risks – The Company has provided for losses for professional liability risks based upon management's best available information including actuarially determined estimates. Ultimate claims costs may differ from the provisions for loss. See Notes 3 and 9.

Income taxes – The Company is subject to various federal and state income tax audits in the ordinary course of business. Such audits could result in increased tax payments, interest and penalties.

Litigation – The Company is a party to various legal actions and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including investigations resulting from the Company's obligation to self-report suspected violations of law by the Company). The Company cannot predict the ultimate outcome of pending litigation and regulatory and other governmental and internal audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties, some of which may not be covered by insurance. The U.S. Department of Justice (the "DOJ"), CMS or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future which may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations and liquidity. See Note 20.

Other indemnifications – In the ordinary course of business, the Company enters into contracts containing standard indemnification provisions and indemnifications specific to a transaction, such as a disposal of an operating facility. These indemnifications may cover claims related to employment-related matters, governmental regulations, environmental issues and tax matters, as well as patient, third party payor, supplier and contractual relationships. Obligations under these indemnities generally are initiated by a breach of the terms of a contract or by a third party claim or event.

#### NOTE 14 - CAPITAL STOCK

#### Dividends

In August 2013, the Company's Board of Directors approved the initiation of a quarterly cash dividend to its shareholders of \$0.12 per common share that was paid on September 9, 2013 to shareholders of record as of the close of business on August 19, 2013. A subsequent quarterly cash dividend of \$0.12 per common share was paid on December 9, 2013 to shareholders of record as of the close of business on November 18, 2013. In February 2014, the Company's Board of Directors approved a quarterly cash dividend to its shareholders of \$0.12 per common share to be paid on March 27, 2014 to shareholders of record as of the close of business on March 6, 2014. Future declarations of quarterly dividends will be subject to the approval of the Company's Board of Directors.

Equity compensation plans

In May 2011, the shareholders of the Company approved an additional three million shares of common stock that could be issued under the Company's incentive compensation plans to Company employees. In May 2012, the shareholders of the Company approved an additional 200,000 shares of common stock that could be issued under the Company's equity compensation plan to the Company's non-employee directors.

#### Plan descriptions

The Company maintains plans under which approximately four million service-based restricted shares, performance-based restricted shares and options to purchase common stock may be granted to directors, officers and other key employees. Exercise provisions vary, but most stock options are exercisable in whole or in part beginning one to four years after grant and ending seven to ten years after grant. Shares of common stock available for future grants were 1,033,186, 2,301,320 and 3,513,109 at December 31, 2013, 2012 and 2011, respectively.

#### Stock options

There were no stock option grants during the three years ended December 31, 2013.

Compensation expense related to stock was immaterial for the year ended December 31, 2013, \$0.1 million (\$0.1 million net of income taxes) for the year ended December 31, 2012 and \$0.3 million (\$0.2 million net of income taxes) for the year ended December 31, 2011.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 14 – CAPITAL STOCK (Continued)

Stock options (Continued)

Activity in the various plans is summarized below:

	Shares		Weighted
	under	Option price	average
	option	per share	exercise price
Balances, December 31, 2012	1,763,497	\$6.10 to \$25.83	\$ 18.16
Exercised	(102,226)	6.49 to 15.06	9.82
Canceled	(638,670)	6.10 to 25.83	16.91
Balances, December 31, 2013	1,022,601	\$11.53 to \$25.83	\$ 19.77

The intrinsic value of the stock options exercised during 2013, 2012 and 2011 approximated \$0.4 million, \$0.2 million and \$2.8 million, respectively. Cash received from stock option exercises in 2013, 2012 and 2011 totaled \$0.5 million, \$0.1 million and \$3.0 million, respectively.

A summary of stock options outstanding at December 31, 2013 follows:

	Options outs	standing		Options exe	rcisable
		Weighted			
	Number	average	Weighted	Number	Weighted
	outstanding	remaining	average	exercisable	average
	at December	36ntractual	exercise	at December	r 8xercise
Range of exercise prices	2013	life	price	2013	price
\$11.53 to \$15.06	267,832	3 years	\$ 14.47	267,832	\$ 14.47
\$18.26 to \$22.72	480,027	1 year	19.40	480,027	19.40
\$23.25 to \$25.83	274,742	1 year	25.58	274,742	25.58
	1,022,601	1 year	\$ 19.77	1,022,601	\$ 19.77

The intrinsic value of the stock options outstanding and stock options that are exercisable as of December 31, 2013 each approximated \$1.8 million.

Service-based restricted shares

At December 31, 2013, unearned compensation costs related to non-vested service-based restricted shares aggregated \$9.0 million. These costs will be expensed over the remaining weighted average vesting period of approximately two years. Compensation expense related to these awards approximated \$9.6 million (\$5.8 million net of income taxes) for the year ended December 31, 2013, \$7.6 million (\$4.6 million net of income taxes) for the year ended December 31, 2011.

A summary of non-vested service-based restricted shares follows:

	Non-vested service-based restricted shares	Weighted average fair value at date of grant
Balances, December 31, 2012	1,566,969	\$ 13.17
Granted	822,633	11.44
Vested	(541,100	) 13.64
Canceled	(67,148	) 13.12
Balances, December 31, 2013	1,781,354	\$ 12.23

The fair value of restricted shares vested during 2013, 2012 and 2011 was \$6.6 million, \$3.2 million and \$7.0 million, respectively.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 14 – CAPITAL STOCK (Continued)

Performance-based restricted shares

Performance-based restricted share awards vest over a three-year period based upon the attainment of various performance measures in each performance period. Compensation expense related to these awards approximated \$1.6 million (\$1.0 million net of income taxes) for the year ended December 31, 2013, \$3.2 million (\$2.0 million net of income taxes) for the year ended December 31, 2012 and \$5.4 million (\$3.3 million net of income taxes) for the year ended December 31, 2011.

A summary of non-vested performance-based restricted shares follows:

	Non-vested performance-based restricted shares	fa	eighted average ir value at te of grant
Balances, December 31, 2012	836,749		Ū
Granted	542,500	\$	10.81
Vested	(344,429)	)	9.39
Canceled	(66,761	\$	10.23
Balances, December 31, 2013	968,059		

The performance measures and fair value for each vesting period of a performance-based restricted share award are established annually. The performance measures and fair value for the non-vested performance-based restricted shares have not been established for vesting periods with performance measures determined after December 31, 2013.

#### NOTE 15 - EMPLOYEE BENEFIT PLANS

The Company maintains defined contribution retirement plans covering employees who meet certain minimum eligibility requirements. Benefits are determined as a percentage of a participant's contributions and generally are vested based upon length of service. Retirement plan expense was \$1.1 million for 2013, \$4.1 million for 2012 and \$5.5 million for 2011. Amounts equal to retirement plan expense are funded annually.

#### NOTE 16 - ACCRUED LIABILITIES

A summary of other accrued liabilities at December 31 follows (in thousands):

	2013	2012	
Accrued litigation	\$40,629	\$9,309	

Edgar Filing: Cejka A Timothy - Form 4

Patient accounts	38,386	43,124
Taxes other than income	37,408	46,114
Accrued interest	11,957	14,096
Other	18,115	24,561
	\$146,495	\$137,204

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 17 – FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company follows the provisions of the authoritative guidance for fair value measurements, which addresses how companies should measure fair value when they are required to use a fair value measure for recognition or disclosure purposes under generally accepted accounting principles.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The guidance related to fair value measures establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:

- Level 1 Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity securities and derivative contracts that are traded in an active exchange market, as well as certain U.S. Treasury, other U.S. Government and agency asset backed debt securities that are highly liquid and are actively traded in over-the-counter markets.
- Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, and other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 17 – FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The Company's assets and liabilities measured at fair value on a recurring and non-recurring basis and any associated losses for the years ended December 31, 2013 and 2012 are summarized below (in thousands):

	Fair value measurements			Assets/ liabilities	Total
	Level 1	Level 2	Level 3	at fair value	losses
December 31, 2013:					
Recurring:					
Assets:					
Available-for-sale debt securities:					
Corporate bonds	\$-	\$20,615	<b>\$</b> -	\$ 20,615	\$-
Debt securities issued by U.S. government agencies	-	19,527	-	19,527	_
U.S. Treasury notes	7,638	_	-	7,638	_
	7,638	40,142	_	47,780	_
Available-for-sale equity securities	9,420	_	-	9,420	_
Money market funds	12,080	_	_	12,080	_
Certificates of deposit	_	3,950	_	3,950	_
Total available-for-sale investments	29,138	44,092	_	73,230	_
Deposits held in money market funds	643	4,238	-	4,881	_
	\$29,781	\$48,330	<b>\$</b> -	\$ 78,111	\$-
Liabilities:					
Interest rate swaps	<b>\$</b> -	\$(1,437)	\$-	\$ (1,437)	\$-
Non-recurring:					
Assets:					
Hospitals available for sale	\$-	\$-	\$3,358	\$ 3,358	\$(9,964)
Property and equipment	-	_	2,888	2,888	(11,743)
Goodwill – home health	_	_	112,378	112,378	(76,082)
	\$-	\$-	\$118,624	\$ 118,624	\$(97,789)
Liabilities	<b>\$</b> -	\$-	\$-	\$ -	\$-
December 31, 2012:					
Recurring:					
Assets:					
Available-for-sale debt securities:					
Corporate bonds	\$-	\$21,454	\$-	\$ 21,454	\$-
Debt securities issued by U.S. government agencies	_	16,713	_	16,713	_
U.S. Treasury notes	6,134	_	_	6,134	_
	6,134	38,167	_	44,301	_
Available-for-sale equity securities	13,025	_	-	13,025	_
Money market funds	7,438	_	_	7,438	_
Certificates of deposit	_	5,104	_	5,104	_
Total available-for-sale investments	26,597	43,271	_	69,868	_
		,		,	

Deposits held in money market funds	347	3,978	_	4,325	_
T in the second	\$26,944	\$47,249	\$-	\$ 74,193	\$-
Liabilities:					
Interest rate swaps	<b>\$</b> -	\$(2,649)	\$-	\$ (2,649	) \$-
Non-recurring:					
Assets:					
Hospital available for sale	\$-	\$-	\$105	\$ 105	\$(569)
Property and equipment	-	_	286	286	(3,630 )
Goodwill – skilled nursing rehabilitation services	-	_	_	-	(107,899)
Intangible assets – Medicare license	_	_	_	_	(2,530)
	\$-	\$-	\$391	\$ 391	\$(114,628)
Liabilities	\$-	<b>\$</b> -	\$-	\$ -	\$-
<i>3</i> -41					

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 17 – FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

#### Recurring measurements

The Company's available-for-sale investments held by its limited purpose insurance subsidiary consist of debt securities, equities, money market funds and certificates of deposit. These available-for-sale investments and the insurance subsidiary's cash and cash equivalents of \$175.7 million as of December 31, 2013 and \$136.5 million as of December 31, 2012, classified as insurance subsidiary investments, are maintained for the payment of claims and expenses related to professional liability and workers compensation risks.

The Company also has available-for-sale investments totaling \$3.6 million as of December 31, 2013 and \$3.7 million as of December 31, 2012 related to a deferred compensation plan that is maintained for certain of the Company's current and former employees.

The fair value of actively traded debt and equity securities and money market funds are based upon quoted market prices and are generally classified as Level 1. The fair value of inactively traded debt securities and certificates of deposit are based upon either quoted market prices of similar securities or observable inputs such as interest rates using either a market or income valuation approach and are generally classified as Level 2. The Company's investment advisors obtain and review pricing for each security. The Company is responsible for the determination of fair value and as such the Company reviews the pricing information from its advisors in determining reasonable estimates of fair value. Based upon the Company's internal review procedures, there were no adjustments to the prices during 2013 or 2012.

The Company's deposits held in money market funds consist primarily of cash and cash equivalents for the Company's insurance programs and for general corporate purposes.

The fair value of the derivative liability associated with the interest rate swaps is estimated using industry-standard valuation models, which are Level 2 measurements. Such models project future cash flows and discount the future amounts to a present value using market-based observable inputs, including interest rate curves. See Note 12.

The following table presents the carrying amounts and estimated fair values of the Company's financial instruments. The carrying value is equal to fair value for financial instruments that are based upon quoted market prices or current market rates. The Company's long-term debt is based upon Level 2 inputs.

	2013		2012	
	Carrying	Fair	Carrying	Fair
(In thousands)	value	value	value	value
Cash and cash				
equivalents	\$35,972	\$35,972	\$50,007	\$50,007
Cash-restricted	3,713	3,713	5,197	5,197
Insurance				
subsidiary				
investments	245,389	245,389	202,592	202,592

Tax refund escrow				
investments	205	205	207	207
Long-term				
debt, including				
amounts due				
within one year				
(excluding				
capital lease				
obligations				
totaling \$0.6				
million at				
December 31,				
2012)	1,587,608	1,630,192	1,657,039	1,630,649

Non-recurring measurements

In connection with the preparation of the Company's operating results for the fourth quarter of 2013, the Company determined that the impact of regulatory changes announced on November 22, 2013 related to the Company's home health reporting unit was an impairment triggering event. The regulatory changes resulted from action by CMS to, among other changes, rebase home health payment rates by reducing the national standardized 60 day episode payment rate by 2.8% in each of the next four years beginning January 1, 2014. The Company tested the recoverability of the home health reporting unit goodwill, other intangible assets and long-lived assets. The Company recorded a pretax impairment charge aggregating \$76.1 million in the fourth quarter of 2013 to reflect the amount by which the carrying value of its home health reporting unit exceeded the estimated fair value. The Company determined that other intangible assets and long-lived assets in the home health reporting unit were not impaired.

KINDRED HEALTHCARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 17 - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Non-recurring measurements (Continued)

In the fourth quarter of 2013, the Company reviewed the long-lived assets related to the planned divestiture and pending offer for a TC hospital held for sale and determined its property and equipment was impaired. As a result, the Company recorded a pretax loss on divestiture of \$8.6 million in discontinued operations. The fair value of the assets were measured using a Level 3 input of the pending offer.

During the year ended December 31, 2013, the Company recorded an asset impairment charge of \$7.9 million related to leasehold improvements of the 2013 Expiring Facilities. These charges reflect the amount by which the carrying value exceeded its estimated fair value. The fair value of property and equipment was measured using Level 3 inputs such as replacement costs adjusted for depreciation, economic obsolescence and inflation.

During the year ended December 31, 2013, the Company reduced the fair value of a hospital held for sale based upon a pending offer, which resulted in a pretax loss of \$1.4 million in other operating expenses in continuing operations. The fair value of the assets were measured using a Level 3 input of the pending offer.

In July 2011, CMS issued the 2011 CMS Rules. The Company recorded pretax impairment charges aggregating \$3.8 million (including \$1.1 million in continuing operations) and \$3.0 million (including \$1.0 million in continuing operations) for the years ended December 31, 2013 and December 31, 2012, respectively, for property and equipment expenditures in the nursing center asset groups that were determined to be impaired by the 2011 CMS Rules. These charges reflected the amount by which the carrying value of certain assets exceeded their estimated fair value. The fair value of property and equipment was measured using Level 3 inputs such as replacement costs factoring in depreciation, economic obsolesce and inflation trends.

At September 30, 2012, the Company reviewed the indefinite-lived and long-lived assets related to the divestiture of a TC hospital and determined its indefinite-lived Medicare license and property and equipment were impaired. As a result, the Company recorded a pretax loss on divestiture of \$3.2 million in discontinued operations. The fair value of the assets were measured using a Level 3 input of the offer.

In September 2012, the Company reduced the fair value of a hospital held for sale based upon a pending offer, which resulted in a pretax loss of \$0.5 million recorded in discontinued operations. The primary reason for the reduction was the general deterioration in the real estate market where the hospital is located. The fair value of the asset was measured using a Level 3 input of the pending offer.

In connection with the preparation of the Company's operating results for the fourth quarter of 2012, the Company determined that the impact of regulatory changes related to the Company's skilled nursing rehabilitation services reporting unit was a triggering event in the fourth quarter of 2012, simultaneously with the Company's annual impairment test. The regulatory changes included a new pre-payment manual medical review process for certain Medicare Part B services exceeding \$3,700 which became effective October 1, 2012 and new rules which became effective April 1, 2013 under the Taxpayer Relief Act that reduced Medicare Part B payments by an additional 25% for subsequent procedures when multiple therapy services are provided on the same day. The Company tested the recoverability of its skilled nursing rehabilitation services reporting unit goodwill, other intangible assets and long-lived assets. The Company recorded a pretax impairment charge aggregating \$107.9 million (which represented

the entire skilled nursing rehabilitation services reporting unit goodwill) in the fourth quarter of 2012 to reflect the amount by which the carrying value of goodwill exceeded the estimated fair value. The impairment charge did not impact the Company's cash flows or liquidity. The fair value of goodwill was measured using both Level 2 and Level 3 inputs such as discounted cash flows, market multiple analysis, replacement costs and sales comparison methodologies.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 18 – NONCONTROLLING INTERESTS

As of December 31, 2013, the Company had ownership ranging from 51% to 99% in various joint ventures.

During 2013, the Company did not complete any buyouts of noncontrolling interests. During 2012, the Company completed various partial buyouts of noncontrolling interests. During 2011, the Company completed two joint venture buyouts, one a full buyout and the other a partial buyout, of noncontrolling interests. In accordance with the authoritative guidance of noncontrolling interests, these payments have been accounted for as equity transactions.

The following table reflects the effects on the Company's equity for the years ended December 31, 2012 and 2011 related to these buyouts in the Company's ownership interest in consolidated subsidiaries (amounts in thousands):

December 31, 2012:

Decrease in carrying value of noncontrolling interests for purchase of noncontrolling interests in subsidiaries \$2,053 Increase in Company's capital in excess of par value for purchase of noncontrolling interests in subsidiaries (1,334)Total cash consideration paid in exchange for purchase of noncontrolling interests \$719

December 31, 2011:

Decrease in carrying value of noncontrolling interests for purchase of noncontrolling interests in subsidiaries \$6,297

Decrease in
Company's capital in
excess of par value
for purchase of
noncontrolling
interests in
subsidiaries 995
Total cash
consideration paid in
exchange for
purchase of
noncontrolling
interests \$7,292

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 19 - CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." The Company's Notes issued on June 1, 2011, are fully and unconditionally guaranteed, subject to certain customary release provisions, by substantially all of the Company's domestic 100% owned subsidiaries. The equity method has been used with respect to the parent company's investment in subsidiaries.

The following condensed consolidating financial data present the financial position of the parent company/issuer, the guarantor subsidiaries and the non-guarantor subsidiaries as of December 31, 2013 and December 31, 2012, and the respective results of operations and cash flows for the three years ended December 31, 2013.

#### Condensed Consolidating Statement of Operations

Year ended	Docombor	21	2013	
- y ear ended	December	ാഥ	. 2015	

				Consolidating		
	Parent			and		
	company/	Guarantor	Non-guarantor	eliminating		
,	issuer	subsidiaries	subsidiaries	adjustments	Consolidated	
Revenues	\$-	\$4,485,614	\$ 530,982	\$ (116,086	) \$4,900,510	
Salaries, wages						
and benefits	_	2,799,131	189,356	_	2,988,487	
Supplies	_	311,374	17,625	_	328,999	
Rent	_	280,231	37,846	_	318,077	
Other						
operating						
expenses	_	853,252	248,717	(116,086	) 985,883	
Other (income)						
expense	_	31	(1,471)	_	(1,440 )	
Impairment						
charges	_	77,193	_	_	77,193	
Depreciation and						
amortization	_	146,707	10,622	_	157,329	
Management						
fees	_	(12,908)	12,908	_	_	
Intercompany						
interest						
(income)						
expense from						
affiliates	(106,068)	70,995	35,073	_	_	
Interest	,					
expense	107,785	52	212	_	108,049	

Investment		<b>(225</b>	`	(2.016	,			(4.051	
income	_	(235	)	(3,816	)	_		(4,051	)
Equity in net									
loss of									
consolidating									
affiliates	167,455	_		_		(167,455	)	_	
	169,172	4,525,823	3	547,072		(283,541	)	4,958,526	
Loss from									
continuing									
operations									
before income									
taxes	(169,172)	(40,209)	)	(16,090	)	167,455		(58,016	)
Provision									
(benefit) for									
income taxes	(680 )	(14,059	)	1,535		_		(13,204	)
Loss from									
continuing									
operations	(168,492)	(26,150	)	(17,625	)	167,455		(44,812	)
Discontinued									
operations, net									
of income									
taxes:									
Loss from									
operations	_	(36,136	)	_		_		(36,136	)
Loss on									
divestiture of									
operations	_	(83,887	)	_		_		(83,887	)
Loss from									
discontinued									
operations	_	(120,023	)	_		_		(120,023	)
Net loss	(168,492)	(146,173	)	(17,625	)	167,455		(164,835	)
Earnings									
attributable to									
noncontrolling									
interests	_	-		(3,657	)	-		(3,657	)
Loss									
attributable to	* (4 50 40 *)	*****						h /	
Kindred	\$(168,492)	\$(146,173	) \$	5 (21,282	) \$	6 167,455		\$ (168,492	)
Comprehensive		<b></b>	`					h /4 62 20 F	
loss	\$(166,862)	\$(146,173	) \$	5 (17,859	) \$	6 167,689		\$ (163,205	)
Comprehensive	e								
loss									
attributable to	Φ /1 CC 2 C2 :	ф /1 4 C 1 = =	, a	(01.51.5	, a	165 600		h /1 / / / / / /	
Kindred	\$(166,862)	\$(146,173	) \$	5 (21,516	) \$	6 167,689		\$ (166,862	)

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Operations (Continued)

### Year ended December 31, 2012

	_			Consolidating	g
	Parent	<b>G</b> .	NT .	and	
(T (1 1)	company/	Guarantor	Non-guarantor	eliminating	C 1:1 4 1
(In thousands)		subsidiaries	subsidiaries	adjustments	Consolidated
Revenues	\$-	\$4,548,839	\$ 480,117	\$ (100,447	) \$4,928,509
Salaries, wages		2 027 507	174724		2 012 221
and benefits	_	2,837,587	174,734	<u> </u>	3,012,321
Supplies	_	307,014	36,088	_	343,102
Rent	_	279,526	30,652	_	310,178
Other					
operating		002 (20	212.001	(100.447	014.070
expenses	_	802,638	212,081	(100,447	) 914,272
Other income	_	(12,660)	_	<del>_</del>	(12,660 )
Impairment		100.052			100.052
charges	_	108,953	_	_	108,953
Depreciation					
and		150 774	11.011		162 605
amortization	_	150,774	11,911	<del>_</del>	162,685
Management	(210	(10.400)	10.501		
fees	(218)	(12,483)	12,701	_	-
Intercompany					
interest					
(income)					
expense from	(112.745)	00.456	22.200		
affiliates	(113,745)	80,456	33,289	_	-
Interest	107.242	0	620		107.075
expense	107,243	2	630	_	107,875
Investment		(116	(001		(007
income	_	(116)	(881	) –	(997)
Equity in net					
loss of					
consolidating	44.651			(44.651	_
affiliates	44,651	-	-	(44,651	) -
T (1 )	37,931	4,541,691	511,205	(145,098	) 4,945,729
Income (loss)	(37,931)	7,148	(31,088	44,651	(17,220 )
from					
continuing					
operations					

1 0 1					
before income					
taxes					
Provision					
(benefit) for	2.126	22.00.7	( <b>7</b>		20 -0-
income taxes	2,436	32,895	(5,624	) –	29,707
Loss from					
continuing					
operations	(40,367	) (25,747	) (25,464	) 44,651	(46,927)
Discontinued					
operations, net					
of income					
taxes:					
Income from					
operations	_	12,348	_	_	12,348
Loss on					
divestiture of					
operations	_	(4,745	) –	-	(4,745)
Income from					
discontinued					
operations	-	7,603	_	_	7,603
Net loss	(40,367	) (18,144	) (25,464	) 44,651	(39,324)
Earnings					
attributable to					
noncontrolling					
interests	-	_	(1,043	) –	(1,043)
Loss					
attributable to					
Kindred	\$(40,367	) \$(18,144	) \$ (26,507	) \$ 44,651	\$ (40,367)
Comprehensive	e				
loss	\$(40,780	) \$(18,490	) \$ (24,627	) \$ 44,160	\$ (39,737)
Comprehensive	e				
loss					
attributable to					
Kindred	\$(40,780	) \$(18,490	) \$ (25,670	) \$ 44,160	\$ (40,780 )

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Operations (Continued)

# Year ended December 31, 2011

	_			Consolidating	,
	Parent	<b>G</b> .	NT.	and	
(T1. 1.)	company/		Non-guarantor	eliminating	G 11.1 . 1
(In thousands)	issuer	subsidiaries	subsidiaries	adjustments	Consolidated
Revenues	\$-	\$3,999,991	\$ 299,760	\$ (87,225	) \$4,212,526
Salaries, wages	8		0.7.40.7		2
and benefits	_	2,481,238	95,435	_	2,576,673
Supplies	_	293,166	20,936	_	314,102
Rent	_	263,627	17,703	_	281,330
Other					
operating					
expenses	-	788,360	151,402	(87,225	) 852,537
Other income	_	(13,180 )	_	_	(13,180)
Impairment					
charges	-	73,554	_	_	73,554
Depreciation					
and					
amortization	_	121,283	7,592	_	128,875
Management					
fees	(555)	(8,014)	8,569	_	_
Intercompany					
interest					
(income)					
expense from					
affiliates	(88,234)	68,650	19,584	_	_
Interest					
expense	80,181	297	422	_	80,900
Investment					
income	_	(70)	(918	) —	(988)
Equity in net					
loss of					
consolidating					
affiliates	59,083	_	_	(59,083	) –
	50,475	4,068,911	320,725	(146,308	) 4,293,803
Loss from	(50,475)	(68,920 )	(20,965	59,083	(81,277)
continuing					
operations					
before income					

Edgar Filing: Cejka A Timothy - Form 4

taxes								
Provision								
(benefit) for								
income taxes	3,006	(11,690	)	(5,357	)	_	(14,041	)
Loss from								
continuing								
operations	(53,481)	(57,230	)	(15,608	)	59,083	(67,236	)
Income from								
discontinued								
operations, net								
of income								
taxes	_	13,517		_		_	13,517	
Net loss	(53,481)	(43,713	)	(15,608	)	59,083	(53,719	)
Loss								
attributable to								
noncontrolling								
interests	-	_		238		-	238	
Loss								
attributable to								
Kindred	\$(53,481)	\$(43,713	) \$	(15,370	)	\$ 59,083	\$ (53,481	)
Comprehensiv								
loss	\$(55,085)	\$(45,006	) \$	(15,919	)	\$ 60,687	\$ (55,323	)
Comprehensiv	e							
loss								
attributable to								
Kindred	\$(55,085)	\$(45,006)	) \$	(15,681	)	\$ 60,687	\$ (55,085	)

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Balance Sheet

### As of December 31, 2013

	Parent			Consolidating and	
	company/	Guarantor	Non-guarantor	eliminating	
(In thousands)		subsidiaries	subsidiaries	adjustments	Consolidated
ASSETS				J	
Current assets:					
Cash and cash					
equivalents	\$-	\$23,535	\$ 12,437	\$-	\$35,972
Cash – restricte	ed-	3,713	_	_	3,713
Insurance					
subsidiary					
investments	_	_	96,295	_	96,295
Accounts					
receivable, net	_	819,103	97,426	_	916,529
Inventories	_	22,870	2,910	_	25,780
Deferred tax					
assets	_	37,920	_	_	37,920
Income taxes	_	36,083	763	_	36,846
Other	_	40,679	2,994	_	43,673
	_	983,903	212,825	_	1,196,728
Property and					
equipment, net	_	878,284	48,291	_	926,575
Goodwill	_	700,278	291,824	_	992,102
Intangible					
assets, net	_	400,313	22,990	_	423,303
Assets held for	•				
sale	_	20,978	-	_	20,978
Insurance					
subsidiary					
investments	_	_	149,094	_	149,094
Investment in					
subsidiaries	55,609	_	_	(55,609)	) —
Intercompany	2,580,391	_	_	(2,580,391)	) –
Deferred tax					
assets	_	6,193	10,850	_	17,043
Other	43,332	104,113	72,601	_	220,046
	\$2,679,332	\$3,094,062	\$ 808,475	\$ (2,636,000)	\$ 3,945,869

Edgar Filing: Cejka A Timothy - Form 4

LIABILITIES					
AND EQUITY	<b>7</b>				
Current					
liabilities:					
Accounts					
payable	\$-	\$158,497	\$ 23,275	\$-	\$ 181,772
Salaries, wages	8				
and other					
compensation	_	314,413	46,779	_	361,192
Due to third					
party payors	_	33,747	_	_	33,747
Professional					
liability risks	_	3,339	57,654	_	60,993
Other accrued					
liabilities	13,378	122,381	10,736	_	146,495
Long-term deb					
due within one					
year	7,875	109	238	_	8,222
	21,253	632,486	138,682	_	792,421
Long-term deb	t 1,575,422	249	3,720	_	1,579,391
Intercompany	_	2,226,940	353,451	(2,580,391	) –
Professional					
liability risks	_	62,115	184,115	_	246,230
Deferred					
credits and					
other liabilities	; –	129,260	77,351	_	206,611
Commitments					
and					
contingencies					
Equity:					
Stockholders'					
equity	1,082,657	43,012	12,597	(55,609	) 1,082,657
Noncontrolling	5				
interests	_	_	38,559	_	38,559
	1,082,657	43,012	51,156	(55,609	) 1,121,216
	\$2,679,332	\$3,094,062	\$ 808,475	\$ (2,636,000	) \$3,945,869

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Balance Sheet (Continued)

#### As of December 31, 2012

	Parent			Consolidating and	
	company/	Guarantor	Non-guarantor	eliminating	
(In thousands)		subsidiaries	subsidiaries	adjustments	Consolidated
ASSETS				<b>g</b>	
Current assets:					
Cash and cash					
equivalents	\$-	\$37,370	\$ 12,637	<b>\$</b> -	\$ 50,007
Cash – restricte	ed-	5,197	_	_	5,197
Insurance					
subsidiary					
investments	_	_	86,168	_	86,168
Accounts					
receivable, net	_	940,524	98,081	_	1,038,605
Inventories	_	29,023	2,998	_	32,021
Deferred tax					
assets	_	12,663	_	_	12,663
Income taxes	_	13,187	386	_	13,573
Other	_	15,118	20,414	_	35,532
	_	1,053,082	220,684	_	1,273,766
Property and					
equipment, net	<u> </u>	1,090,523	52,603	_	1,143,126
Goodwill	_	771,533	269,733	_	1,041,266
Intangible					
assets, net	_	417,092	22,675	_	439,767
Assets held for					
sale	_	4,131	_	_	4,131
Insurance					
subsidiary					
investments	_	_	116,424	_	116,424
Investment in					
subsidiaries	221,581	_	_	(221,581)	) –
Intercompany	2,655,460	_	_	(2,655,460)	) —
Deferred tax					
assets	1,040	_	13,932	(14,972	_
Other	47,364	108,143	63,959	_	219,466
	\$2,925,445	\$3,444,504	\$ 760,010	\$ (2,892,013)	\$ 4,237,946

LIABILITIES	-				
AND EQUITY					
Current liabilities:					
Accounts					
payable	\$168	\$195,268	\$ 15,232	<b>\$</b> —	\$ 210,668
Salaries, wages		\$193,200	\$ 13,232	<b>y</b> –	\$ 210,000
and other					
compensation	_	345,223	43,786	_	389,009
Due to third		3 13,223	15,700		307,007
party payors	_	35,420	_	_	35,420
Professional		, -			,
liability risks	_	3,623	50,465	_	54,088
Other accrued					
liabilities	16,724	111,113	9,367	_	137,204
Long-term deb	t				
due within one					
year	8,000	102	840	_	8,942
	24,892	690,749	119,690	_	835,331
Long-term deb	t 1,644,394	358	3,954	_	1,648,706
Intercompany	_	2,328,929	326,531	(2,655,460	) –
Professional		60.116	160 711		226.620
liability risks	_	68,116	168,514	_	236,630
Deferred tax		04.726		(14.070	0.764
liabilities	_	24,736	_	(14,972	) 9,764
Deferred credits and					
other liabilities		143,722	70,949		214,671
Commitments	_	143,722	70,545	_	214,071
and					
contingencies					
Equity:					
Stockholders'					
equity	1,256,159	187,894	33,687	(221,581	) 1,256,159
Noncontrolling		·		,	
interests	_	_	36,685	-	36,685
	1,256,159	187,894	70,372	(221,581	) 1,292,844
	\$2,925,445	\$3,444,504	\$ 760,010	\$ (2,892,013	) \$4,237,946

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Cash Flows

Year ended December 31, 2013	Yea	ar ended	Decem	ber 31	, 2013
------------------------------	-----	----------	-------	--------	--------

	Parent			Consolidating and	
	company/	Guarantor	Non-guarantor	eliminating	
(In thousands)	issuer	subsidiaries	subsidiaries	adjustments	Consolidated
Net cash					
provided by					
(used in)					
operating	<b>4.4.5</b> 00		A 20 00 F	Φ.	<b>0.100.110</b>
activities	\$(1,290	\$ 171,717	\$ 28,985	\$ -	\$199,412
Cash flows					
from investing					
activities:					
Routine capital expenditures		(96,051)	(4,857)		(100,908)
Development	_	(96,051)	(4,637	_	(100,908)
capital					
expenditures		(11,206)	(618)		(11,824)
Acquisitions,		(11,200	(010		(11,024
net of cash					
acquired	_	(223,917)	(402)	_	(224,319 )
Sale of assets	_	250,606	_	_	250,606
Purchase of		200,000			200,000
insurance					
subsidiary					
investments	_	_	(46,127)	_	(46,127)
Sale of					
insurance					
subsidiary					
investments	_	_	49,954	_	49,954
Net change in					
insurance					
subsidiary cash	l				
and cash					
equivalents	_	_	(44,077)	_	(44,077 )
Change in					
other		100			122
investments	_	122	<del>_</del>	14 220	122
	_	(14,220 )	_	14,220	_

Capital										
contribution to insurance										
subsidiary										
Other	_		376		_		_		376	
Net cash used										
in investing										
activities	_		(94,290	)	(46,127	)	14,220		(126,197	)
Cash flows										
from financing activities:										
Proceeds from										
borrowings										
under										
revolving										
credit	1,675,800		_		_		_		1,675,800	
Repayment of										
borrowings										
under revolving										
credit	(1,740,400	))	_		_		_		(1,740,400	)
Repayment of	(-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,							(-,, :,, :,,	
other long-term										
debt	(5,938	)	(102	)	(836	)	-		(6,876	)
Payment of										
deferred	(1.666	\							(1.666	`
financing costs Distribution	(1,000	)	_		_		_		(1,666	)
made to										
noncontrolling										
interests	_		_		(2,051	)	_		(2,051	)
Issuance of										
common stock			_		_		_		461	
Dividends paid	(13,001	)	_		_		_		(13,001	)
Change in intercompany										
accounts	86,034		(91,643	)	5,609		_		_	
Capital	00,00		(>1,0.0	,	2,003					
contribution to										
insurance										
subsidiary	_		_		14,220		(14,220	)	_	
subsidiary Other	_ _		- 483		14,220		(14,220	)	- 483	
subsidiary Other Net cash	_ _		- 483		14,220		(14,220	)	- 483	
subsidiary Other Net cash provided by	- -		483		14,220		(14,220	)	483	
subsidiary Other Net cash	_		483		14,220		(14,220	)	483	
subsidiary Other Net cash provided by (used in)	1,290		- 483 (91,262	)	14,220 - 16,942		(14,220 - (14,220	)	- 483 (87,250	)
subsidiary Other Net cash provided by (used in) financing activities Change in cash	1,290			)	-		-			)
subsidiary Other Net cash provided by (used in) financing activities Change in cash and cash	1,290		(91,262	)	16,942		-		(87,250	)
subsidiary Other Net cash provided by (used in) financing activities Change in cash	1,290			)	-	)	-			)

Cash and cash					
equivalents at					
beginning of					
period					
Cash and cash					
equivalents at					
end of period	\$-	\$23,535	\$ 12,437	\$ -	\$35,972

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Cash Flows (Continued)

Vann	ended	D	aaml		21	2017	)
rear	ended	Dt	сени	)er	ЭΙ.	. 2012	_

	Parent			Consolidating and	
	company/	Guarantor	Non-guarantor	eliminating	
(In thousands)	issuer	subsidiaries	subsidiaries	adjustments	Consolidated
Net cash					
provided by					
operating					
activities	\$23,683	\$210,573	\$ 28,306	\$ -	\$262,562
Cash flows					
from investing					
activities:					
Routine capital					
expenditures	_	(106,075)	(9,100)	_	(115,175)
Development					
capital					
expenditures	_	(44,860)	(5,462)	_	(50,322)
Acquisitions,					
net of cash					
acquired	_	(178,212)	_	-	(178,212)
Sale of assets	_	1,260	_	_	1,260
Purchase of					
insurance					
subsidiary					
investments	_	_	(38,041)	_	(38,041)
Sale of					
insurance					
subsidiary					
investments	_	_	38,363	_	38,363
Net change in					
insurance					
subsidiary cash	l				
and cash					
equivalents	_	_	(21,285)	_	(21,285)
Change in					
other					
investments	_	1,465	_	_	1,465
Capital	_	(8,600)	-	8,600	_
contribution to					

insurance										
subsidiary			(520	\					(520	\
Other	_		(539	)	<del>-</del>		_		(539	)
Net cash used										
in investing			(225 5(1	`	(25 525	`	0.600		(262.496	\
activities	_		(335,561	)	(35,525	)	8,600		(362,486	)
Cash flows										
from financing activities:										
Proceeds from										
borrowings										
under										
revolving										
credit	1,784,300		_		_		_		1,784,300	
Repayment of	1,704,500								1,707,500	
borrowings										
under										
revolving										
credit	(1,757,100	)	_		_		_		(1,757,100	)
Proceeds from	(1,707,100	,							(1,707,100	
issuance of										
term loan, net										
of discount	97,500		_		_		_		97,500	
Repayment of										
other long-term										
debt	(7,000	)	(95	)	(3,569	)	_		(10,664	)
Payment of										
deferred										
financing costs	(1,465	)	_		_		_		(1,465	)
Contribution										
made by										
noncontrolling										
interests	_		_		200		_		200	
Distribution										
made to										
noncontrolling										
interests	-		_		(3,829	)	-		(3,829	)
Purchase of										
noncontrolling					<b>(=10</b>				( <b>=</b> 10	
interests	_		_		(719	)	_		(719	)
Issuance of	1.47								1.47	
common stock	147		_		_		_		147	
Capital										
contribution to										
insurance					0.600		(0,600	\		
subsidiary Change in	<u> </u>		<del>-</del>		8,600		(8,600	)	_	
Change in										
intercompany accounts	(140,065	`	140,628		(563	)				
Net cash	(23,683	)	140,628		120	)	(8,600	)	108,370	
provided by	(23,003	,	170,333		120		(0,000	,	100,570	
provided by										

Edgar Filing: Cejka A Timothy - Form 4

(used in) financing activities					
Change in cash and cash equivalents	1 _	15,545	(7,099	) –	8,446
Cash and cash equivalents at beginning of period	_	21,825	19,736	<u>-</u>	41,561
Cash and cash equivalents at end of period	\$-	\$37,370	\$ 12,637	\$ -	\$ 50,007

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

# NOTE 19 – CONDENSED CONSOLIDATING FINANCIAL INFORMATION (Continued)

Condensed Consolidating Statement of Cash Flows (Continued)

Vasuanda	d Daggarda	21	2011
r ear ende	ed Decembe	r o L	. 2011

	Parent			Consolidating and	5
(In thousands)	company/	Guarantor subsidiaries	Non-guarantor subsidiaries	eliminating adjustments	Consolidated
Net cash	ISSUCI	subsidiaries	substaties	adjustifients	Consolidated
provided by					
(used in)					
operating					
activities	\$(34,018	) \$175,419	\$ 15,805	\$ (3,500	) \$153,706
Cash flows					
from investing					
activities:					
Routine capital					
expenditures	_	(128,976)	(3,927)	_	(132,903)
Development					
capital		(07.655			(97.655
expenditures	<del>-</del>	(87,655)	_	_	(87,655)
Acquisitions, net of cash					
acquired		(745,630)	30,172		(715,458 )
Sale of assets	_	1,714	50,172	_	1,714
Purchase of		1,717			1,717
insurance					
subsidiary					
investments	_	_	(35,623	· –	(35,623)
Sale of			,		
insurance					
subsidiary					
investments	_	_	46,307	_	46,307
Net change in					
insurance					
subsidiary cash	l				
and cash			(1.1.2.1.2		(1.1.2.1.2
equivalents	_	_	(14,213)	_	(14,213)
Change in					
other		1,003			1 002
investments Other	_	(512)	_	_	1,003 (512 )
Other	_	(312	_	_	(312

Net cash provided by						
(used in)						
investing						
activities	_	(960,056)	22,716		_	(937,340 )
Cash flows						
from financing activities:						
Proceeds from						
borrowings						
under						
revolving						
credit	2,126,800	_	_		_	2,126,800
Repayment of						
borrowings under						
revolving						
credit	(2,198,300)	_	_		_	(2,198,300)
Proceeds from						
issuance of						
senior						
unsecured	550,000					550,000
notes Proceeds from	330,000	_	_		_	330,000
issuance of						
term loan, net						
of discount	693,000	_	_		_	693,000
Repayment of						
other long-term debt	(2.500	(245 460 )	(1.000	`		(250.979
Payment of	(3,500)	(345,469)	(1,909	)	_	(350,878)
deferred						
financing costs	(9,098)	_	_		_	(9,098)
Purchase of						
noncontrolling			<b>(7.000</b>			( <b>7.00</b>
interests Issuance of	_	<del>_</del>	(7,292	)	_	(7,292 )
common stock	3,019	_	_		_	3,019
Change in	3,017					3,017
intercompany						
accounts	(1,128,679)	1,134,763	(6,084	)	_	_
Insurance						
subsidiary			(2.500	,	2.500	
distribution Other	776	_	(3,500	)	3,500	- 776
Net cash	770	_	_		_	770
provided by						
(used in)						
financing						
activities	34,018	789,294	(18,785	)	3,500	808,027
	_	4,657	19,736		_	24,393

Edgar Filing: Cejka A Timothy - Form 4

Change in cash and cash equivalents	l				
Cash and cash equivalents at					
beginning of					
period	_	17,168	_	_	17,168
Cash and cash equivalents at					
end of period	\$-	\$21,825	\$ 19,736	\$ -	\$41,561

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 20 - LEGAL AND REGULATORY PROCEEDINGS

The Company provides services in a highly regulated industry and is subject to various legal actions and regulatory and other governmental and internal audits and investigations from time to time. These matters could (1) require the Company to pay substantial damages, fines, penalties or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under the Company's insurance policies where coverage applies and is available; (2) cause the Company to incur substantial expenses; (3) require significant time and attention from the Company's management; (4) subject the Company to sanctions including possible exclusions from the Medicare and Medicaid programs; and (5) cause the Company to close or sell one or more facilities or otherwise modify the way the Company conducts business. The ultimate resolution of these matters, whether as a result of litigation or settlement, could have a material adverse effect on the Company's business, financial position, results of operations and liquidity.

In accordance with authoritative accounting guidance related to loss contingencies, the Company records an accrued liability for litigation and regulatory matters that are both probable and reasonably estimable. Additional losses in excess of amounts accrued may be reasonably possible. The Company reviews loss contingencies that are reasonably possible and determines whether an estimate of the possible loss or range of loss, individually or in aggregate, can be disclosed in the Company's consolidated financial statements. These estimates are based upon currently available information for those legal and regulatory proceedings in which the Company is involved, taking into account the Company's best estimate of losses for those matters for which such estimate can be made. The Company's estimates involve significant judgment, given that (1) these legal and regulatory proceedings are in early stages; (2) discovery may not be completed; (3) damages sought in these legal and regulatory proceedings can be unsubstantiated or indeterminate; (4) the matters present legal uncertainties or evolving areas of law; (5) there are often significant facts in dispute; and/or (6) there is a wide range of possible outcomes. Accordingly, the Company's estimated loss or range of loss may change from time to time, and actual losses may be more or less than the current estimate. At this time, except as otherwise specifically noted, no estimate of the possible loss or range of loss, individually or in the aggregate, in excess of the amounts accrued, if any, can be made regarding the matters described below.

Set forth below are descriptions of the Company's significant legal proceedings.

Medicare and Medicaid payment reviews, audits and investigations—as a result of the Company's participation in the Medicare and Medicaid programs, the Company faces and is currently subject to various governmental and internal reviews, audits and investigations to verify the Company's compliance with these programs and applicable laws and regulations. The Company is routinely subject to audits under various government programs, such as the CMS Recovery Audit Contractor program, in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments to healthcare providers under the Medicare program. In addition, the Company, like other hospital and nursing center operators and rehabilitation therapy service providers, is subject to ongoing investigations by the U.S. Department of Health and Human Services Office of Inspector General (the "OIG"), the DOJ and state attorneys general into the billing of rehabilitation and other services provided to Medicare and Medicaid patients, including whether rehabilitation therapy services were properly documented and billed, whether services provided were medically necessary and general compliance with conditions of participation in the Medicare and Medicaid programs. Private pay sources such as third party insurance and managed care entities also often reserve the right to conduct audits. The Company's costs to respond to and defend any such reviews, audits and investigations are significant and are likely to increase in the current enforcement environment. These audits and investigations may require the Company to refund or retroactively adjust amounts that

have been paid under the relevant government program or by other payors. Further, an adverse review, audit or investigation also could result in other adverse consequences, particularly if the underlying conduct is found to be pervasive or systemic. These consequences include (1) state or federal agencies imposing fines, penalties and other sanctions on the Company, (2) loss of the Company's right to participate in the Medicare or Medicaid programs or one or more third party payor networks, (3) indemnity claims asserted by customers and others for which the Company provides services, and (4) damage to the Company's reputation in various markets, which could adversely affect the Company's ability to attract patients, residents and employees.

Whistleblower lawsuits—the Company is also subject to qui tam or "whistleblower" lawsuits under the False Claims Act and comparable state laws for allegedly submitting fraudulent bills for services to the Medicare and Medicaid programs. These lawsuits can result in monetary damages, fines, attorneys' fees and the award of bounties to private qui tam plaintiffs who successfully bring these lawsuits and to the respective government programs. The Company also could be subject to civil penalties (including the loss of the Company's licenses to operate one or more facilities or healthcare activities), criminal penalties (for violations of certain laws and regulations), and exclusion of one or more facilities or healthcare activities from participation in the Medicare, Medicaid and other federal and state healthcare programs. The lawsuits are in various stages of adjudication or investigation and involve a wide variety of claims and potential outcomes.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 20 – LEGAL AND REGULATORY PROCEEDINGS (Continued)

A whistleblower lawsuit previously pending against RehabCare, a therapy services company acquired by the Company on June 1, 2011, and two unrelated defendant companies in federal district court for the Eastern District of Missouri was settled in January 2014. The lawsuit pertained to a subcontractor arrangement entered in 2006 by RehabCare and another unrelated therapy services provider, and fees paid under and in connection with the transaction. The complaint alleged civil violations of the federal False Claims Act based upon an underlying claim that the transaction violated the federal Anti-Kickback Statute. Based upon the results of certain pre-trial motions, new facts associated with the case and settlement discussions occurring in September 2013, the Company recorded an additional \$23 million loss provision in the third quarter of 2013 (for a total loss reserve of \$25 million) related to this matter. In January 2014, the lawsuit was settled with the Company's payment of \$25 million to the United States and \$150,000 to the whistleblower's attorneys and was dismissed by the court with prejudice.

Employment-related lawsuits—the Company's operations are subject to a variety of federal and state employment-related laws and regulations, including but not limited to the U.S. Fair Labor Standards Act, Equal Employment Opportunity laws and enforcement policies of the Equal Employment Opportunity Commission, the Office of Civil Rights and state attorneys general, federal and state wage and hour laws and a variety of laws enacted by the federal and state governments that govern these and other employment-related matters. Accordingly, the Company is currently subject to employee-related claims, class action and other lawsuits and proceedings in connection with the Company's operations, including but not limited to those related to alleged wrongful discharge, illegal discrimination and violations of equal employment and federal and state wage and hour laws. Because labor represents such a large portion of the Company's operating costs, non-compliance with these evolving federal and state laws and regulations could subject the Company to significant back pay awards, fines and additional lawsuits and proceedings. These claims, lawsuits and proceedings are in various stages of adjudication or investigation and involve a wide variety of claims and potential outcomes.

Four wage and hour class action lawsuits are currently pending against the Company in federal district court for the Central District of California, and are being addressed together by the court. Each case pertains to alleged errors made by the Company with respect to regular pay and overtime pay calculations, waiting times, meal period waivers and wage statements under California law. On March 13, 2013, the court conditionally certified five classes of the seven total classes sought for certification for discovery purposes and declined to certify two others. Notice of class action certification and class members' right to opt out of the lawsuit was mailed to all of the Company's current and former California hospital employees. The Company intends to vigorously defend these claims.

A wage and hour class action lawsuit against the Company alleging violations of federal and state wage and hour laws is pending in federal district court for the Northern District of Illinois. This lawsuit pertains to the Company's previous automatic meal break deduction practice for non-exempt employees in the Company's hospitals located outside California. The court granted conditional class certification in part on June 11, 2013. This lawsuit has been settled in principle by the Company's agreement to pay \$0.7 million to claimants from the Company's five Illinois hospitals, plaintiffs' attorney's fees and certain administrative costs, subject to reaching a written settlement agreement and obtaining court approval.

Based upon available information, the Company recorded an additional \$7.0 million loss provision in the fourth quarter of 2013 (for a total loss reserve of \$12.7 million) related to these wage and hour lawsuits. The Company continues to evaluate the loss provision in light of potentially relevant factual and legal developments, including

information learned through rulings on dispositive motions, settlement discussions and other rulings. The expected loss reserve is based upon currently available information and is subject to significant judgment and a variety of assumptions, and known and unknown uncertainties. Given the uncertainty of litigation, the actual loss may vary significantly from the current reserve, which does not represent the Company's maximum loss exposure. At this time, no estimate of the possible loss or range of loss, in excess of the amount accrued, can be made regarding these lawsuits.

Minimum staffing lawsuits—various states in which the Company operates hospitals and nursing centers have established minimum staffing requirements or may establish minimum staffing requirements in the future. While the Company seeks to comply with all applicable staffing requirements, the regulations in this area are complex and the Company may experience compliance issues from time to time. Failure to comply with such minimum staffing requirements may result in one or more facilities failing to meet the conditions of participation under relevant federal and state healthcare programs and the imposition of significant fines, damages or other sanctions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### NOTE 20 – LEGAL AND REGULATORY PROCEEDINGS (Continued)

Ordinary course matters—in addition to the matters described above, the Company is subject to investigations, claims and lawsuits in the ordinary course of business, including professional liability claims and investigations resulting from the Company's obligation to self-report suspected violations of law by the Company, particularly in the Company's hospital and nursing center operations. In many of these claims, plaintiffs' attorneys are seeking significant fines and compensatory and punitive damages, along with attorneys' fees. The Company maintains professional and general liability insurance in amounts and coverage that management believes are sufficient for the Company's operations. However, the Company's insurance may not cover all claims against the Company or the full extent of the Company's liability.

On January 6, 2014, a purported class action complaint was filed in the United States federal district court for the Southern District of Florida, Miami Division, against the Company and one of its subsidiaries. The lawsuit, styled Pines Nursing Home, et al., v. Polaris and RehabCare Group, Inc., et al., alleges that one of the Company's subsidiaries sent "junk" faxes in violation of the Telephone Consumer Protection Act of 1991 and the Junk Fax Prevention Act of 2005. The complaint seeks damages, statutory fines and penalties, attorneys' fees and an injunction prohibiting such conduct in the future. The Company disputes the allegations in the complaint and will defend this lawsuit vigorously.

### QUARTERLY CONSOLIDATED FINANCIAL INFORMATION (UNAUDITED)

(In thousands, except per share amounts)

The following table represents summary quarterly consolidated financial information (unaudited) for the years ended December 31, 2013 and 2012:

	2013 (a)			<b>T</b>
D	First	Second	Third	Fourth
Revenues Net income (loss):	\$1,278,327	\$1,207,979	\$1,189,830	\$1,224,374
Income (loss) from continuing operations	10,698	13,565	(17,338)	(51,737)
Discontinued operations, net of income taxes:	10,096	15,303	(17,336)	(31,737 )
Loss from operations	(5,200	(886	(23,890)	(6,160)
Loss on divestiture of operations	12122		1 - 1 - 1	, ,
Loss from discontinued operations	(2,025) $(7,225)$	, , ,	, , ,	
Net income (loss)	3,473	1,827	(106,244)	, , ,
Earnings attributable to noncontrolling interests	(416)		(100,244)	
Income (loss) attributable to Kindred	3,057	1,745	(106,998)	
Earnings (loss) per common share:	3,037	1,743	(100,996)	(00,290)
Basic:				
Income (loss) from continuing operations	0.19	0.25	(0.34)	(1.04)
Discontinued operations:	0.17	0.23	(0.54	(1.04 )
Loss from operations	(0.09	(0.02)	(0.46)	(0.12)
Loss on divestiture of operations	(0.04)	` '	(0.40)	,
Loss from discontinued operations	(0.13)	` '	(1.70)	` '
Net income (loss)	0.06	0.03	(2.04)	` '
Diluted:	0.00	0.02	(2.0.	(1.27)
Income (loss) from continuing operations	0.19	0.25	(0.34)	(1.04)
Discontinued operations:	0.15	0.20	(6.6.	(110 1
Loss from operations	(0.09	(0.02	(0.46)	(0.12)
Loss on divestiture of operations	(0.04		(1.24)	
Loss from discontinued operations	(0.13	` ,	(1.70	,
Net income (loss)	0.06	0.03	(2.04	(1.27)
Shares used in computing earnings (loss) per common share:			,	
Basic	52,062	52,265	52,323	52,344
Diluted	52,083	52,284	52,323	52,344
Market prices:				
High	11.74	14.49	16.63	20.51
Low	10.21	9.75	12.50	13.13
	2012 (a) First	Second	Third	Fourth
Revenues	\$1,257,132	\$1,218,336	\$1,215,649	\$1,237,392

Net income (loss):								
Income (loss) from continuing operations	17,375		10,573		8,334		(83,209	)
Discontinued operations, net of income taxes:								
Income from operations	2,437		5,046		1,553		3,312	
Loss on divestiture of operations	(1,170	)	(356	)	(2,280)	)	(939	)
Income (loss) from discontinued operations	1,267		4,690		(727	)	2,373	
Net income (loss)	18,642		15,263		7,607		(80,836	)
(Earnings) loss attributable to noncontrolling interests	(451	)	239		(41	)	(790	)
Income (loss) attributable to Kindred	18,191		15,502		7,566		(81,626	)
Earnings (loss) per common share:								
Basic:								
Income (loss) from continuing operations	0.32		0.20		0.16		(1.62	)
Discontinued operations:								
Income from operations	0.05		0.10		0.02		0.06	
Loss on divestiture of operations	(0.02)	)	(0.01)	)	(0.04)	)	(0.02)	)
Income (loss) from discontinued operations	0.03		0.09		(0.02)	)	0.04	
Net income (loss)	0.35		0.29		0.14		(1.58	)
Diluted:								
Income (loss) from continuing operations	0.32		0.20		0.16		(1.62	)
Discontinued operations:								
Income from operations	0.05		0.10		0.02		0.06	
Loss on divestiture of operations	(0.02)	)	(0.01)	)	(0.04)	)	(0.02)	)
Income (loss) from discontinued operations	0.03		0.09		(0.02)	)	0.04	
Net income (loss)	0.35		0.29		0.14		(1.58	)
Shares used in computing earnings (loss) per common share:								
Basic	51,603		51,664		51,676		51,692	
Diluted	51,638		51,675		51,709		51,692	
Market prices:								
High	13.62		10.87		12.76		12.13	
Low	8.63		7.60		8.80		9.68	

<sup>(</sup>a) See accompanying discussion of certain quarterly items.

#### KINDRED HEALTHCARE, INC.

#### QUARTERLY CONSOLIDATED FINANCIAL INFORMATION (UNAUDITED) (Continued)

(In thousands, except per share amounts)

#### SIGNIFICANT QUARTERLY ADJUSTMENTS

The following is a description of significant quarterly adjustments recorded during 2013 and 2012:

Fourth quarter 2013

Operating results for the fourth quarter of 2013 included pretax charges related to costs incurred in connection with the closing of a TC hospital of \$0.5 million, a litigation charge of \$7.0 million, severance and retirement costs of \$3.7 million, transaction-related costs of \$0.4 million and an impairment charge of \$76.1 million.

Third quarter 2013

Operating results for the third quarter of 2013 included pretax charges related to costs incurred in connection with the closing of a TC hospital of \$5.5 million, litigation charges of \$23.8 million, severance and retirement costs of \$1.9 million, \$0.5 million of costs associated with closing a home health location, \$0.6 million of fees and charges associated with the modification of certain of the Company's senior debt and transaction-related costs of \$0.6 million.

Second quarter 2013

Operating results for the second quarter of 2013 included pretax charges related to charges associated with the modification of certain of the Company's senior debt of \$1.4 million and transaction-related costs of \$0.1 million.

First quarter 2013

Operating results for the first quarter of 2013 included pretax charges related to one-time bonus costs paid to employees who do not participate in the Company's incentive compensation program of \$20.1 million and transaction-related costs of \$1.0 million.

Fourth quarter 2012

Operating results for the fourth quarter of 2012 included pretax charges related to employee severance costs of \$3.4 million and contract cancellation costs of \$0.9 million incurred in connection with restructuring activities, transaction-related costs of \$0.6 million, a lease cancellation charge of \$0.1 million and impairment charges of \$107.9 million.

Third quarter 2012

Operating results for the third quarter of 2012 included pretax charges related to transaction-related costs of \$0.5 million and a lease cancellation charge of \$0.6 million.

Second quarter 2012

Operating results for the second quarter of 2012 included pretax charges related to employment-related lawsuits of \$5.0 million, costs incurred in connection with the closing of two TC hospitals of \$1.4 million, the cancellation of a sub-acute unit project of \$0.9 million, transaction-related costs of \$0.6 million and a lease cancellation charge of \$0.9 million.

First quarter 2012

Operating results for the first quarter of 2012 included pretax charges related to costs incurred in connection with the closing of a regional office of \$2.2 million and transaction-related costs of \$0.5 million.

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2013, 2012 AND 2011

(In thousands)

		Additions				
		Charged t	0			
	Balance at	costs				Balance at
	beginning	and			Deductions	end of
	of period	expenses	Other	Acquisitions	or payments	period
Allowance for loss on accounts receivable	·:					
Year ended December 31, 2011	\$ 13,584	\$35,133	\$-	\$ -	\$ (18,971)	\$ 29,746
Year ended December 31, 2012	29,746	23,692	_	_	(29,479)	23,959
Year ended December 31, 2013	23,959	44,640	_	_	(27,574)	41,025
Allowance for deferred taxes:						
Year ended December 31, 2011	\$ 38,431	\$-	\$163 (a)	\$ 112	\$ (75)	\$ 38,631
Year ended December 31, 2012	38,631	_	7,352(a)	3,031	(37)	48,977
Year ended December 31, 2013	48,977	_	379 (a)	872	(485)	49,743

<sup>(</sup>a) The Company identified deferred income tax assets for state income tax NOLs of \$56.7 million, \$52.7 million and \$42.1 million at December 31, 2013, December 31, 2012 and December 31, 2011, respectively, and a corresponding deferred income tax valuation allowance of \$49.5 million, \$48.4 million and \$38.0 million at December 31, 2013, December 31, 2012 and December 31, 2011, respectively, after determining that a portion of these state net deferred income tax assets were not realizable. The Company identified deferred income tax assets for federal income tax NOLs of \$25.5 million at December 31, 2013 and a corresponding deferred income tax valuation allowance of \$0.2 million at December 31, 2013 after determining that a portion of these federal net deferred income tax assets were not realizable.